Why Is GSK Plc Up Today?

GSK Plc (LSE:GSK) shares rose 0.66% to 1,902.5p today, with attention on the pharmaceutical group's latest quarterly update and its continuing shift towards specialty medicines. The move follows a third-quarter report in which management reaffirmed its 2026 guidance.

GSK reported Q3 2026 turnover of £8,887m, up 5% at constant exchange rates, and core operating profit of £3,076m, also up 5%. Core Earnings Per Share were 54.6p, while total operating profit fell 16% at constant exchange rates to £2,127m, reflecting restructuring charges linked to the Accelerate Growth programme.

The gain therefore sits alongside a Business that is delivering growth in its priority areas while managing a period of portfolio change. Defensive healthcare names have often attracted attention when investors reassess the balance between growth and risk across the wider stock market.

About GSK Plc

GSK Plc is a global biopharmaceutical company headquartered in the UK, focused on discovering, developing and supplying vaccines and medicines.

Its business is organised around three commercial areas: Specialty Medicines, Vaccines and General Medicines. Therapy areas include HIV, respiratory, immunology and inflammation, oncology and infectious disease.

Chief Executive Luke Miels leads a group that generated Q3 turnover of £8.9 billion and nine-month turnover of £24,925m, giving LSE:GSK a large and diversified Revenue base.

Key Reasons Behind Today's Uptick

Today's 0.66% gain is modest, and it comes shortly after the company confirmed that its 2026 outlook remains intact.

Pharmaceutical shares are often treated as a defensive part of the stock market, and sector rotation can influence trading in large UK healthcare names on any given day.

Investors are also looking at the mix of growth in the latest quarter, where specialty medicines, oncology and respiratory products delivered double-digit growth while some Vaccine lines remained under pressure.

Q3 2026 Results Overview

In the third quarter, GSK delivered turnover growth of 5% at constant exchange rates, with core operating profit up 5% to £3,076m and a core Operating Margin of 34.6%.

Core EPS of 54.6p was 1% higher at constant exchange rates, while total EPS of 38.5p was lower year-on-year because of the restructuring charges.

Cash generated from operations rose 24% to £3,122m, and free Cash Flow for the quarter was £2.1 billion, giving the group room to fund its pipeline and dividend.

Nine-Month Performance

For the first nine months of 2026, turnover reached £24,925m, up 5% at constant exchange rates.

Core operating profit increased 7% to £8,526m with a margin of 34.2%, while core EPS rose 6% to 151.6p.

Total operating profit was £4,901m, lower than a year earlier, which highlights the gap between reported and core measures as restructuring costs flow through.

Specialty Medicines Lead Growth

Specialty Medicines was the standout division, with Q3 sales of £3.9 billion, up 15%.

HIV sales were £2.1 billion, up 10%, while Respiratory, Immunology and Inflammation grew 21% to £1.1 billion. Oncology sales rose 23% to £0.6 billion.

This broadening of growth beyond HIV is important for LSE:GSK because it supports the transition towards a more diversified specialty portfolio.

Vaccines and General Medicines

Vaccines sales were £2.6 billion in Q3, down 2%. Shingrix sales of £0.8 billion fell 5%, and Arexvy sales of £0.2 billion declined 24%, while meningitis vaccines grew 12% to £0.6 billion.

General Medicines sales were stable at £2.4 billion, with Trelegy contributing £0.8 billion, up 8%.

The vaccine Franchise remains a significant earnings contributor, and management continues to guide for vaccines to be broadly stable to up low single digits for the full year.

Cash Generation and Restructuring

Cash generation is an important support for the Investment case. Cash generated from operations was £7,378m in the first nine months of 2026, up 18% on the prior year.

The gap between core and total profit reflects restructuring charges of £328m in the quarter linked to the Accelerate Growth programme.

Management uses core measures to show underlying performance, so investors typically follow both the core and total figures to understand how quickly restructuring costs fall away.

Over time, the programme is intended to simplify the organisation and direct spending towards the products and therapy areas with the greatest growth potential.

HIV and Respiratory Franchises

HIV remains GSK's largest therapy area, with Q3 sales of £2.1 billion, up 10%. The franchise is a major contributor to profitability and cash flow.

In respiratory medicine, Trelegy added £0.8 billion of sales, up 8%, while the wider Respiratory, Immunology and Inflammation grouping grew 21%.

The long-term challenge for LSE:GSK is to sustain growth in these franchises while newer medicines scale up ahead of the 2028 to 2030 dolutegravir exclusivity period.

Pipeline and Regulatory Progress

GSK reported several regulatory milestones in the period. Hibsago was approved in the US and Japan for chronic hepatitis B, and Jemperli was approved in the US for adults with dMMR/MSI-H locally advanced rectal cancer.

Jideytro reported positive registrational data in first-line ROS1-positive non-small cell lung cancer, following a US approval in the second-line setting in July.

An mRNA seasonal flu vaccine has entered phase III, and GSK expects to start 22 phase III trials in 2026, with 18 already under way.

2026 Guidance and Dividend

GSK reaffirmed its 2026 guidance at constant exchange rates. Turnover is expected to grow 3% to 5% in the upper half of that range, and core operating profit is expected to grow 7% to 9%, also in the upper half.

Core EPS growth of 7% to 9% is now expected in the lower half of its range.

A Q3 Dividend of 17p per share was declared, up 1p, and the company expects a total of 70p for 2026. Shareholder returns are therefore a visible part of the investment case for LSE:GSK.

Long-Term Outlook

GSK has set an outlook for sales of more than £40 billion by 2031.

Management expects its operating margin to be stable to improving through the 2028 to 2030 period, when dolutegravir loses exclusivity.

Delivering on that outlook depends on new launches, pipeline progress and the continued expansion of specialty and oncology medicines.

Key Growth Catalysts

The first catalyst is continued growth in specialty medicines, particularly oncology, respiratory and immunology.

The second is pipeline delivery. A large number of phase III trials and recent approvals give GSK several opportunities to refresh its portfolio.

A third is cost discipline, with the Accelerate Growth programme intended to improve efficiency and redeploy spending into higher-growth areas.

Healthcare Sector Exposure

As a global pharmaceutical group, GSK is affected by healthcare policy, drug pricing discussions, regulatory decisions and currency movements.

Royalty income of around £900m expected in 2026 adds another earnings stream, while guidance for interest charges of £700m to £750m and a tax rate of around 17.5% frames the path from operating profit to earnings.

These factors make GSK sensitive to both clinical outcomes and the wider policy environment for medicines.

Risks

Patent expiries are a central risk. The loss of dolutegravir exclusivity later this decade will need to be offset by new products.

Vaccine performance is another consideration, as lower sales of Shingrix and Arexvy show how sensitive the segment can be to Demand and competition.

Clinical trial outcomes, regulatory timing, pricing pressure and restructuring execution may all influence the pace of growth.

Conclusion

GSK Plc's 0.66% rise to 1,902.5p follows a quarter of 5% turnover growth, 5% growth in core operating profit and a reaffirmed 2026 outlook.

Specialty Medicines grew 15%, cash generation improved and the pipeline continues to produce approvals and late-stage trial activity.

The key factors to monitor are the performance of vaccines, the pace of specialty growth, delivery against 2026 guidance, dividend progress and preparation for the dolutegravir exclusivity period.